News 6/29/23
This week, Equitas Health Interim CEO & Chief Advancement Officer Robert Copeland informed the Board of Trustees that he has elected to step down.
The Board thanks Robert for his many years of service and wishes him well as he moves on to other endeavors. The Board has engaged a national search firm to identify a permanent successor. In the interim, the Board is confident in the leadership team’s ability to maintain continuity for our patients, communities and teams throughout this transition, with an unrelenting focus on our mission to provide quality, affirming care for all.
The Board understands that patients and community partners may have questions about next steps in Equitas Health leadership, and it welcomes this feedback. To share your questions and concerns, please email board@equitashealth.com. All correspondence goes directly to Board members, who will make every effort to respond promptly.
Blog 7/29/24
Equitas Health, Ohio’s largest LGBTQ+ and HIV-serving healthcare organization, has announced new officers on the Board of Trustees. Susan McManus (she/her), vice president of business solutions marketing at Nationwide, will serve as Board chair for a one-year term through July 2025.
Blog 3/25/24
Blog 2/26/24
Public Statement 8/26/24
Johnson & Johnson, one of the world’s largest drugmakers, announced last Friday that it will discontinue upfront 340B pricing on two medications for disproportionate share hospital (DSH) covered entities. The move is part of a sustained campaign by large drug manufacturers to undermine the federal 340B Drug Pricing Program for participating hospitals and covered entities such as Equitas Health.
Public Statement 8/14/24
